Dr. Kasra Karamlou

General Surgery
Office
2205 NE 129th St, 
Vancouver, WA 
Office
2205 NE 129th St, 
Vancouver, WA 

Overview

Kasra Karamlou is a General Surgeon practicing medicine in Vancouver, Washington.

His clinical expertise encompasses Small Lymphocytic Lymphoma (SLL).

He is actively involved in clinical research, co-authoring 3 peer reviewed articles and participating in 7 clinical trials.

Specialties

General Surgery

Licenses

Podiatrist in WA

Languages Spoken

English

Gender

Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem BCBS
  • EPO
  • HMO
  • POS
  • PPO
CareSource
  • HMO
Cigna
  • EPO
  • HMO
  • PPO
Devoted Health
  • MEDICARE MAPD
  • OTHER MEDICARE
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medical Mutual
  • HMO
  • PPO
Oscar
  • EPO
  • HMO
  • PPO
SummaCare
  • HMO
  • PPO
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 7 Less Insurance Carriers -

Locations

Office
2205 NE 129th St, Vancouver, WA 98686

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

7 Clinical Trials

Randomized Double-Blind Phase III Trial of Vitamin D3 Supplementation in Patients With Previously Untreated Metastatic Colorectal Cancer (SOLARIS)
Randomized Double-Blind Phase III Trial of Vitamin D3 Supplementation in Patients With Previously Untreated Metastatic Colorectal Cancer (SOLARIS)
Enrollment Status: Active_not_recruiting
Publish Date: March 03, 2026
Intervention Type: Other, Dietary supplement, Drug
Study Drugs: Bevacizumab, Oxaliplatin, Leucovorin calcium, Fluorouracil, Irinotecan hydrochloride, Irinotecan
Study Phase: Phase 3
A Randomized Phase III Trial for Surgically Resected Early Stage Non-small Cell Lung Cancer: Crizotinib Versus Observation for Patients With Tumors Harboring the Anaplastic Lymphoma Kinase (ALK) Fusion Protein
A Randomized Phase III Trial for Surgically Resected Early Stage Non-small Cell Lung Cancer: Crizotinib Versus Observation for Patients With Tumors Harboring the Anaplastic Lymphoma Kinase (ALK) Fusion Protein
Enrollment Status: Active_not_recruiting
Publish Date: December 19, 2025
Intervention Type: Other, Drug
Study Drug: Crizotinib
Study Phase: Phase 3
A Randomized, Open-Label, Phase 3 Study of Abemaciclib Combined With Standard Adjuvant Endocrine Therapy Versus Standard Adjuvant Endocrine Therapy Alone in Patients With High Risk, Node Positive, Early Stage, Hormone Receptor Positive, Human Epidermal Receptor 2 Negative, Breast Cancer
A Randomized, Open-Label, Phase 3 Study of Abemaciclib Combined With Standard Adjuvant Endocrine Therapy Versus Standard Adjuvant Endocrine Therapy Alone in Patients With High Risk, Node Positive, Early Stage, Hormone Receptor Positive, Human Epidermal Receptor 2 Negative, Breast Cancer
Enrollment Status: Active_not_recruiting
Publish Date: April 20, 2025
Intervention Type: Drug
Study Drugs: Abemaciclib, Standard Adjuvant Endocrine Therapy
Study Phase: Phase 3
A Randomized Phase 2/3 Multi-Center Study of SM-88 in Subjects With Pancreatic Cancer Whose Disease Has Progressed or Recurred
A Randomized Phase 2/3 Multi-Center Study of SM-88 in Subjects With Pancreatic Cancer Whose Disease Has Progressed or Recurred
Enrollment Status: Terminated
Publish Date: November 06, 2024
Intervention Type: Drug
Study Drugs: SM-88, MPS (methoxsalen, phenytoin, sirolimus), Capecitabine, Gemcitabine, 5-FU
Study Phase: Phase 2/Phase 3
A Phase 1/2, Open-Label, Uncontrolled, Multiple Dose Escalation, Cohort Expansion Study To Evaluate The Safety, Tolerability, Pharmacokinetics And Preliminary Efficacy Of ASN002 In Relapsed/Refractory Lymphoma, Myelofibrosis, Chronic Lymphocytic Leukemia, And Advanced Solid Tumors
A Phase 1/2, Open-Label, Uncontrolled, Multiple Dose Escalation, Cohort Expansion Study To Evaluate The Safety, Tolerability, Pharmacokinetics And Preliminary Efficacy Of ASN002 In Relapsed/Refractory Lymphoma, Myelofibrosis, Chronic Lymphocytic Leukemia, And Advanced Solid Tumors
Enrollment Status: Terminated
Publish Date: June 07, 2023
Intervention Type: Drug
Study Phase: Phase 1/Phase 2
A Phase 2 Study of Duvelisib Efficacy and Safety in Patients With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL) Previously Treated With a Bruton's Tyrosine Kinase Inhibitor (BTKi)
A Phase 2 Study of Duvelisib Efficacy and Safety in Patients With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL) Previously Treated With a Bruton's Tyrosine Kinase Inhibitor (BTKi)
Enrollment Status: Withdrawn
Publish Date: February 28, 2023
Intervention Type: Drug
Study Phase: Phase 2
An Open-Label Phase 2 Study of Itacitinib (INCB039110) in Combination With Low-Dose Ruxolitinib or Itacitinib Alone Following Ruxolitinib in Subjects With Myelofibrosis
An Open-Label Phase 2 Study of Itacitinib (INCB039110) in Combination With Low-Dose Ruxolitinib or Itacitinib Alone Following Ruxolitinib in Subjects With Myelofibrosis
Enrollment Status: Completed
Publish Date: June 16, 2022
Intervention Type: Drug
Study Drugs: Itacitinib, Ruxolitinib
Study Phase: Phase 2
View 6 Less Clinical Trials

3 Total Publications

Carfilzomib in combination with R-CHOP for initial treatment of patients with non-germinal center diffuse large B-cell lymphoma: a multicenter, single arm, phase 1/2 study.
Carfilzomib in combination with R-CHOP for initial treatment of patients with non-germinal center diffuse large B-cell lymphoma: a multicenter, single arm, phase 1/2 study.
Journal: Leukemia & lymphoma
Published: May 21, 2025
Similar Doctors
Expertise in
13
conditions
Dr. Steven Demeester
General Surgery
Expertise in
13
conditions
Dr. Steven Demeester
General Surgery
Referral may be required

Office

4805 NE Glisan St Ste 6N60, 
Portland, OR 
 (13.1 miles away)
503-281-0561
Languages Spoken:
English
See accepted insurances

Steven Demeester is a General Surgeon practicing medicine in Portland, Oregon. Dr. Demeester is highly rated in 13 conditions, according to our data. His clinical expertise encompasses Hiatal Hernia, Diaphragmatic Hernia, Hernia, Endoscopy, and Gastrectomy.

Expertise in
12
conditions
Dr. Lee Swanstrom
General Surgery
Expertise in
12
conditions
Dr. Lee Swanstrom
General Surgery
Referral may be required

Office

4805 NE Glisan St Ste 6N60, 
Portland, OR 
 (13.1 miles away)
503-281-0561
Languages Spoken:
English

Lee Swanstrom is a General Surgeon practicing medicine in Portland, Oregon. Dr. Swanstrom is highly rated in 12 conditions, according to our data. His clinical expertise encompasses Achalasia, Hiatal Hernia, Diaphragmatic Hernia, Endoscopy, and Gallbladder Removal.

Expertise in
25
conditions
Dr. John Vetto
General Surgery
Expertise in
25
conditions
Dr. John Vetto
General Surgery
Referral may be required

OHSU Hospital

3181 SW Sam Jackson Park Rd, 
Portland, OR 
 (15.1 miles away)
503-494-5501
Experience:
44+ years
Languages Spoken:
English
See accepted insurances
Offers Telehealth

John Vetto is a General Surgeon practicing medicine in Portland, Oregon. He has been practicing medicine for over 44 years. Dr. Vetto is highly rated in 25 conditions, according to our data. His clinical expertise encompasses Melanoma, Adult Soft Tissue Sarcoma, Epithelioid Sarcoma, Lymphadenectomy, and Parathyroidectomy.

Frequently Asked Questions about Dr. Kasra Karamlou

How do I make an appointment with Dr. Kasra Karamlou?

You can book an appointment with Dr. Kasra Karamlou by calling their office at 360-450-6644. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Kasra Karamlou a top-rated expert for Small Lymphocytic Lymphoma (SLL)?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Kasra Karamlou is classified as an Experienced expert for Small Lymphocytic Lymphoma (SLL), meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Kasra Karamlou specialize in?

While Dr. Kasra Karamlou is a General Surgery, they have specific expertise in Small Lymphocytic Lymphoma (SLL). MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within General Surgery.

Does Dr. Kasra Karamlou participate in research or clinical trials?

Yes. Dr. Kasra Karamlou has published 3 articles and abstracts on conditions like Small Lymphocytic Lymphoma (SLL). You can view a list of Dr. Kasra Karamlou's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. Kasra Karamlou accept my insurance?

Dr. Kasra Karamlou accepts most major insurance plans, including Aetna and Anthem BCBS. We recommend calling the office directly at 360-450-6644 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Karamlou's expertise for a condition
ConditionClose
        Want to save this doctor for later?
        Sign Up
        Is this your doctor?
        Find A Second Opinion
        Not sure about your diagnosis?
        Check Your Symptoms
         
         
         
         
        Learn about our expert tiers
        Learn More
        Are you the provider on this profile?
        Claim Profile